Andreas Argyrides
Stock Analyst at Wedbush
(4.42)
# 250
Out of 4,826 analysts
100
Total ratings
49.41%
Success rate
23.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $14.58 | +2.88% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $170.74 | +6.01% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $14.70 | +138.10% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $2.69 | +868.34% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $7.85 | -10.83% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $1.08 | +1,474.07% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $16.11 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $41.88 | +148.33% | 14 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $0.88 | +468.50% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $1.25 | +620.00% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $14.27 | +33.19% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $2.83 | +218.02% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.17 | +51.28% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.80 | +114.29% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $63.66 | +251.87% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.72 | +121.62% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.07 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.13 | +522.22% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.98 | +101.01% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.72 | +1,288.89% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $62.06 | +12.79% | 6 | Aug 1, 2023 | |
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $14.58
Upside: +2.88%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $170.74
Upside: +6.01%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $14.70
Upside: +138.10%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $2.69
Upside: +868.34%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $7.85
Upside: -10.83%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $1.08
Upside: +1,474.07%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $16.11
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $41.88
Upside: +148.33%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.88
Upside: +468.50%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.25
Upside: +620.00%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $14.27
Upside: +33.19%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $2.83
Upside: +218.02%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.17
Upside: +51.28%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.80
Upside: +114.29%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $63.66
Upside: +251.87%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.72
Upside: +121.62%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.07
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.13
Upside: +522.22%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $4.98
Upside: +101.01%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.72
Upside: +1,288.89%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $62.06
Upside: +12.79%